{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:38:07Z","timestamp":1771954687827,"version":"3.50.1"},"reference-count":207,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/136007\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136007\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECINST\/00091\/2018"],"award-info":[{"award-number":["CEECINST\/00091\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Center IPO-Porto","award":["PI112-CI-IPOP-92-2018-MCTKidCan"],"award-info":[{"award-number":["PI112-CI-IPOP-92-2018-MCTKidCan"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more efficient patient management. Nonetheless, currently available tools provide limited information and novel strategies are needed. Over the years, a putative role of non-coding RNAs (ncRNAs) as disease biomarkers has gained relevance and is now one of the most prolific fields in biological sciences. Herein, we extensively sought the most significant reports on ncRNAs as potential RCTs\u2019 diagnostic, prognostic, predictive, and monitoring biomarkers. We could conclude that ncRNAs, either alone or in combination with currently used clinical and pathological parameters, might represent key elements to improve patient management, potentiating the implementation of precision medicine. Nevertheless, most ncRNA biomarkers require large-scale validation studies, prior to clinical implementation.<\/jats:p>","DOI":"10.3390\/cancers12082214","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:25:03Z","timestamp":1597044303000},"page":"2214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4508-8301","authenticated-orcid":false,"given":"Gon\u00e7alo","family":"Outeiro-Pinho","sequence":"first","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-0820","authenticated-orcid":false,"given":"Margareta P.","family":"Correia","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira n. 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira n. 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcancer.2012.06.003","article-title":"Genomics and epigenomics of renal cell carcinoma","volume":"23","author":"Maher","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00216-1","article-title":"Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma","volume":"44","author":"Patard","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncponc0926","article-title":"Interleukin 2 for patients with renal cancer","volume":"4","author":"Rosenberg","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100839","DOI":"10.1016\/j.eucr.2019.100839","article-title":"Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report","volume":"24","author":"Ikarashi","year":"2019","journal-title":"Urol. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.seminoncol.2013.05.004","article-title":"Adjuvant Therapy in Renal Cell Carcinoma\u2014Past, Present, and Future","volume":"40","author":"Janowitz","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamaoncol.2016.4419","article-title":"Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma","volume":"3","author":"Chamie","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jamaoncol.2017.0076","article-title":"Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial","volume":"3","author":"Haas","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","article-title":"Adjuvant Sunitinib for High-risk Renal Cell Carcinoma after Nephrectomy: Subgroup Analyses and Updated Overall Survival Results","volume":"73","author":"Motzer","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2011.06.017","article-title":"ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease","volume":"60","author":"Patard","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/j.clgc.2018.01.016","article-title":"Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis","volume":"16","author":"Ratta","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/thy.11.32","article-title":"mTOR inhibitors in renal cell carcinoma","volume":"8","author":"Battelli","year":"2011","journal-title":"Therapy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an Anti\u2013Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"543","article-title":"Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in Cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fgene.2012.00094","article-title":"The Epigenetics of Renal Cell Tumors: From Biology to Biomarkers","volume":"3","author":"Henrique","year":"2012","journal-title":"Front. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrneph.2016.168","article-title":"The epigenetic landscape of renal cancer","volume":"13","author":"Morris","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.canlet.2011.12.026","article-title":"Epigenetic biomarkers in urological tumors: A systematic review","volume":"342","author":"Henrique","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","article-title":"Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches","volume":"96","author":"Beermann","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrm3679","article-title":"RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts","volume":"14","author":"Geisler","year":"2013","journal-title":"Nat. Rev. Mol. Cell Boil."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrg3079","article-title":"Evolution of microRNA diversity and regulation in animals","volume":"12","author":"Berezikov","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tcb.2014.11.004","article-title":"The biological functions of miRNAs: Lessons from in vivo studies","volume":"25","author":"Vidigal","year":"2014","journal-title":"Trends Cell Boil."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrm2632","article-title":"Biogenesis of small RNAs in animals","volume":"10","author":"Kim","year":"2009","journal-title":"Nat. Rev. Mol. Cell Boil."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg2916","article-title":"Small RNA sorting: Matchmaking for Argonautes","volume":"12","author":"Czech","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrg2521","article-title":"Long non-coding RNAs: Insights into functions","volume":"10","author":"Mercer","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrg.2015.10","article-title":"Unique features of long non-coding RNA biogenesis and function","volume":"17","author":"Quinn","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semcdb.2017.07.035","article-title":"Non-coding RNAs as a new dawn in tumor diagnosis","volume":"78","author":"Grimaldi","year":"2018","journal-title":"Semin. Cell Dev. Boil."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41580-019-0106-6","article-title":"Publisher Correction: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Boil."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Boil."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation","volume":"9","author":"Hayder","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0960-9822(01)00299-8","article-title":"Double-stranded RNA-mediated silencing of genomic tandem repeats and transposable elements in the D. melanogaster germline","volume":"11","author":"Aravin","year":"2001","journal-title":"Curr. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.1129333","article-title":"A Distinct Small RNA Pathway Silences Selfish Genetic Elements in the Germline","volume":"313","author":"Vagin","year":"2006","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nature04917","article-title":"A germline-specific class of small RNAs binds mammalian Piwi proteins","volume":"442","author":"Girard","year":"2006","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41576-018-0073-3","article-title":"PIWI-interacting RNAs: Small RNAs with big functions","volume":"20","author":"Ozata","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down\u2013regulation of micro\u2013 RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"(2013). The Cancer Genome Atlas Research Network; Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43\u201349.","DOI":"10.1038\/nature12222"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biocel.2008.09.005","article-title":"DNA methylomes, histone codes and miRNAs: Tying it all together","volume":"41","author":"Guil","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","article-title":"Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival","volume":"64","author":"Takamizawa","year":"2004","journal-title":"Cancer Res."},{"key":"ref_48","first-page":"317","article-title":"Non\u2013coding MicroRNAs hsa\u2013let\u20137g and hsa\u2013miR\u2013181b are Associated with Chemoresponse to S\u20131 in Colon Cancer","volume":"3","author":"Nakajima","year":"2006","journal-title":"Cancer Genom. Proteom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.18632\/aging.102417","article-title":"Emerging roles of piRNAs in cancer: Challenges and prospects","volume":"11","author":"Cheng","year":"2019","journal-title":"Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.2147\/CMAR.S209300","article-title":"The emerging roles of PIWI-interacting RNA in human cancers","volume":"11","author":"Yu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-015-0180-3","article-title":"Piwi\u2013interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas","volume":"34","author":"Busch","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2119\/molmed.2014.00203","article-title":"Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival","volume":"21","author":"Li","year":"2015","journal-title":"Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.21873\/anticanres.11239","article-title":"Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma","volume":"36","author":"Iliev","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cca.2012.11.010","article-title":"Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy","volume":"416","author":"Wotschofsky","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/bjc.2013.552","article-title":"MicroRNA profile: A promising ancillary tool for accurate renal cell tumour diagnosis","volume":"109","author":"Luis","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1111\/j.1582-4934.2009.00705.x","article-title":"MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy","volume":"13","author":"Jung","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2353\/jmoldx.2010.090187","article-title":"Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression","volume":"12","author":"Fridman","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jmoldx.2012.02.003","article-title":"The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma","volume":"14","author":"Faragalla","year":"2012","journal-title":"J. Mol. Diagn."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/bjc.2013.313","article-title":"MicroRNA profiles classify papillary renal cell carcinoma subtypes","volume":"109","author":"Wach","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zaravinos, A., Lambrou, G.I., Mourmouras, N., Katafygiotis, P., Papagregoriou, G., Giannikou, K., Delakas, D., and Deltas, C. (2014). New miRNA Profiles Accurately Distinguish Renal Cell Carcinomas and Upper Tract Urothelial Carcinomas from the Normal Kidney. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091646"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-13-3224","article-title":"miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression","volume":"20","author":"Chen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00432-014-1690-7","article-title":"miR\u2013129\u20133p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis\u2013related genes","volume":"140","author":"Chen","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Vergho, D., Kneitz, S., Kalogirou, C., Burger, M., Krebs, M., Rosenwald, A., Spahn, M., L\u00f6ser, A., Kocot, A., and Riedmiller, H. (2014). Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109877"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/hsz-2015-0284","article-title":"Clinical evaluation of microRNA-145 expression in renal cell carcinoma: A promising molecular marker for discriminating and staging the clear cell histological subtype","volume":"397","author":"Papadopoulos","year":"2016","journal-title":"Boil. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Liep, J., Kilic, E., Meyer, H.A., Busch, J., Jung, K., and Rabien, A. (2016). Cooperative Effect of miR\u2013141\u20133p and miR\u2013145\u20135p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157801"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bju.13886","article-title":"Profiling microRNA from nephrectomy and biopsy specimens: Predictors of progression and survival in clear cell renal cell carcinoma","volume":"120","author":"Kowalik","year":"2017","journal-title":"BJU Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3269379","article-title":"MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma","volume":"2017","author":"Toraih","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_68","first-page":"2092","article-title":"A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization","volume":"9","author":"Saleeb","year":"2017","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2017.03.013","article-title":"Serum microRNA Expression Profiling: Potential Diagnostic Implications of a Panel of Serum microRNAs for Clear Cell Renal Cell Cancer","volume":"104","author":"Yadav","year":"2017","journal-title":"Urology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/1535-7163.MCT-17-0400","article-title":"MicroRNA\u2013720 Regulates E\u2013cadherin\u2013alphaE\u2013catenin Complex and Promotes Renal Cell Carcinoma","volume":"16","author":"Bhat","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1535-7163.MCT-17-0925","article-title":"MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma","volume":"17","author":"Dasgupta","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1158\/1541-7786.MCR-17-0762","article-title":"Elevated miR\u2013182\u20135p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT\u20131 Expression","volume":"16","author":"Kulkarni","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_73","first-page":"1666","article-title":"miR\u2013224\/miR\u2013141 ratio as a novel diagnostic biomarker in renal cell carcinoma","volume":"16","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-018-0906-x","article-title":"Sunitinib\u2013suppressed miR\u2013452\u20135p facilitates renal cancer cell invasion and metastasis through modulating SMAD4\/SMAD7 signals","volume":"17","author":"Zhai","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00345-018-2575-1","article-title":"Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma","volume":"37","author":"Zhao","year":"2018","journal-title":"World J. Urol."},{"key":"ref_76","first-page":"4458","article-title":"The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma","volume":"233","author":"Li","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wulfken, L.M., Moritz, R., Ohlmann, C., Holdenrieder, S., Jung, V., Becker, F., Herrmann, E., Walgenbach-Br\u00fcnagel, G., Von Ruecker, A., and M\u00fcller, S.C. (2011). MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025787"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexmp.2012.10.005","article-title":"Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma","volume":"94","author":"Zhao","year":"2013","journal-title":"Exp. Mol. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.euf.2016.09.007","article-title":"MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma","volume":"4","author":"Zhang","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/CBM-160676","article-title":"Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma","volume":"18","author":"Tusong","year":"2017","journal-title":"Cancer Biomark."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"36.e7","DOI":"10.1016\/j.urolonc.2016.07.012","article-title":"miR\u2013144\u20133p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma","volume":"35","author":"Lou","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.euf.2015.11.006","article-title":"Exosomal MicroRNAs Are Diagnostic Biomarkers and Can Mediate Cell\u2013Cell Communication in Renal Cell Carcinoma","volume":"2","author":"Butz","year":"2016","journal-title":"Eur. Urol. Focus"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11255-018-1841-x","article-title":"MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma","volume":"50","author":"Mytsyk","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-10-55","article-title":"Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma","volume":"10","author":"Redova","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2013.2169","article-title":"Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma","volume":"44","author":"Iwamoto","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1007\/s13277-013-1531-3","article-title":"Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients","volume":"35","author":"Teixeira","year":"2013","journal-title":"Tumor Boil."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1038\/srep07610","article-title":"A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.3390\/ijms161023382","article-title":"Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma","volume":"16","author":"Fedorko","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_89","first-page":"294","article-title":"Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma","volume":"35","author":"Li","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.11613\/BM.2017.043","article-title":"Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma","volume":"27","author":"Fedorko","year":"2017","journal-title":"Biochem. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/ijc.30845","article-title":"Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease","volume":"141","author":"Chanudet","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/jcb.27347","article-title":"Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma","volume":"120","author":"Wang","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_93","first-page":"5075","article-title":"Identification of dysregulated serum miR\u2013508\u20133p and miR\u2013885\u20135p as potential diagnostic biomarkers of clear cell renal carcinoma","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_94","first-page":"15","article-title":"Prognostic urinary miRNAs for the assessment of small renal masses","volume":"75","author":"Brown","year":"2019","journal-title":"Clin. Biochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13046-020-01600-3","article-title":"MicroRNA\u201330a\u20135p(me): A novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples","volume":"39","author":"Aznar","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11255-012-0374-y","article-title":"Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma","volume":"45","author":"Wang","year":"2013","journal-title":"Int. Urol. Nephrol."},{"key":"ref_97","first-page":"3318","article-title":"Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmoldx.2014.10.005","article-title":"miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma","volume":"17","author":"Samaan","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"103315","DOI":"10.18632\/oncotarget.21733","article-title":"Plasmatic miR-210, miR-221 and miR-1233 profile: Potential liquid biopsies candidates for renal cell carcinoma","volume":"8","author":"Dias","year":"2017","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ajpath.2018.07.026","article-title":"Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR\u2013155\u20135p and miR\u2013210\u20133p to both Tumorigenesis and Recurrence","volume":"188","author":"Zhang","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/bjc.2013.56","article-title":"miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis","volume":"108","author":"McCormick","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21645","DOI":"10.18632\/oncotarget.4064","article-title":"Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma","volume":"6","author":"Nakata","year":"2015","journal-title":"Oncotarget"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1442-2042.2012.03182.x","article-title":"MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma","volume":"20","author":"Shinmei","year":"2012","journal-title":"Int. J. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1038\/onc.2010.305","article-title":"Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma","volume":"29","author":"Hildebrandt","year":"2010","journal-title":"Oncogene"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wu, X., Weng, L., Li, X., Guo, C., Pal, S.K., Jin, J.M., Li, Y., Nelson, R.A., Mu, B., and Onami, S.H. (2012). Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035661"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.2012.537","article-title":"Hsa\u2013mir\u2013124\u20133 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma","volume":"108","author":"Gebauer","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/mco.2012.46","article-title":"Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma","volume":"1","author":"Goto","year":"2012","journal-title":"Mol. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Vergho, D.C., Kneitz, S., Rosenwald, A., Scherer, C., Spahn, M., Burger, M., Riedmiller, H., and Kneitz, B. (2014). Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-25"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.ejca.2014.03.281","article-title":"The miR(21\/10b) ratio as a prognostic marker in clear cell renal cell carcinoma","volume":"50","author":"Fritz","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/cas.12507","article-title":"Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection","volume":"105","author":"Fu","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_111","first-page":"758","article-title":"Down-regulation of miR-497 is associated with poor prognosis in renal cancer","volume":"8","author":"Zhao","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajpath.2014.11.017","article-title":"Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma","volume":"185","author":"Khella","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yang, F.-Q., Zhang, H.-M., Chen, S.-J., Yan, Y., and Zheng, J.-H. (2015). MiR\u2013506 is down\u2013regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129404"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13000-015-0255-7","article-title":"miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF","volume":"10","author":"Xu","year":"2015","journal-title":"Diagn. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1038\/srep10272","article-title":"Prognostic value of meta-signature miRNAs in renal cell carcinoma: An integrated miRNA expression profiling analysis","volume":"5","author":"Tang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"12543","DOI":"10.18632\/oncotarget.3815","article-title":"miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT","volume":"6","author":"Butz","year":"2015","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/cam4.631","article-title":"MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma","volume":"5","author":"Khella","year":"2016","journal-title":"Cancer Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3892\/ijo.2016.3746","article-title":"miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN\/SMAD4 expression","volume":"49","author":"Ma","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_119","first-page":"e86051","article-title":"Deep sequencing reveals microRNAs predictive of antiangiogenic drug response","volume":"1","author":"Beuselinck","year":"2016","journal-title":"JCI Insight"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jclinpath-2017-204341","article-title":"miR-10b is a prognostic marker in clear cell renal cell carcinoma","volume":"70","author":"Khella","year":"2017","journal-title":"J. Clin. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/ijc.30853","article-title":"DNA\u2013methylation\u2013mediated repression of miR\u2013766\u20133p promotes cell proliferation via targeting SF2 expression in renal cell carcinoma","volume":"141","author":"Chen","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.biopha.2018.03.072","article-title":"miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma","volume":"102","author":"Pan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_123","first-page":"1874","article-title":"Identification of miR-18a-5p as an oncogene and prognostic biomarker in RCC","volume":"10","author":"Zhou","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.biopha.2018.05.082","article-title":"Oncogenic miR-663a is associated with cellular function and poor prognosis in renal cell carcinoma","volume":"105","author":"Zhou","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_125","first-page":"3092","article-title":"microRNA-572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis","volume":"40","author":"Pan","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.biopha.2018.11.065","article-title":"MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC","volume":"110","author":"Quan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/CBM-182047","article-title":"Upregulation of miR\u2013183\u20135p predicts worse survival in patients with renal cell cancer after surgery","volume":"24","author":"Li","year":"2019","journal-title":"Cancer Biomark."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e16008","DOI":"10.1097\/MD.0000000000016008","article-title":"Expression of microRNA-3133 correlates with the prognosis in patients with clear cell renal cell carcinoma","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"109406","DOI":"10.1016\/j.biopha.2019.109406","article-title":"miR\u2013221\u20135p acts as an oncogene and predicts worse survival in patients of renal cell cancer","volume":"119","author":"Liu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1724600819866456","article-title":"miR\u2013142\u20133p as a novel biomarker for predicting poor prognosis in renal cell carcinoma patients after surgery","volume":"34","author":"Peng","year":"2019","journal-title":"Int. J. Biol. Markers"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"152391","DOI":"10.1016\/j.prp.2019.03.019","article-title":"Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients","volume":"215","author":"Liu","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1245\/s10434-019-07578-3","article-title":"4-miRNA Score Predicts the Individual Metastatic Risk of Renal Cell Carcinoma Patients","volume":"26","author":"Heinzelmann","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"63703","DOI":"10.18632\/oncotarget.19476","article-title":"Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"109877","DOI":"10.18632\/oncotarget.22436","article-title":"Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma","volume":"8","author":"Fujii","year":"2017","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13148-018-0444-9","article-title":"Serum miR\u2013122\u20135p and miR\u2013206 expression: Non\u2013invasive prognostic biomarkers for renal cell carcinoma","volume":"10","author":"Heinemann","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_136","first-page":"51","article-title":"Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma","volume":"2","author":"Schwandt","year":"2009","journal-title":"OncoTargets Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_139","unstructured":"Institute, N.C. (2020, April 01). Precision Medicine in Cancer Treatment, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/precision-medicine."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fonc.2018.00327","article-title":"The Network of Non-coding RNAs in Cancer Drug Resistance","volume":"8","author":"Agnoletto","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-019-0748-z","article-title":"Noncoding RNAs in cancer therapy resistance and targeted drug development","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01171-z","article-title":"Role of non-coding RNAs and RNA modifiers in cancer therapy resistance","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.juro.2012.11.133","article-title":"A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance","volume":"189","author":"Berkers","year":"2013","journal-title":"J. Urol."},{"key":"ref_144","first-page":"1","article-title":"miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib","volume":"2015","author":"Hezova","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12253-017-0323-2","article-title":"Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma","volume":"25","author":"Go","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1593\/neo.12734","article-title":"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients","volume":"14","author":"Bayona","year":"2012","journal-title":"Neoplasia"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1973947813Y.0000000092","article-title":"miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O","volume":"25","author":"Chen","year":"2013","journal-title":"J. Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Prior, C., Perez-Gracia, J.L., Garc\u00eda-Don\u00e1s, J., Rodriguez-Antona, C., Guruceaga, E., Esteban, E., Su\u00e1rez, C., Castellano, D., Del Alba, A.G., and Lozano, M.D. (2014). Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086263"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4149\/neo_2014_083","article-title":"MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1","volume":"61","author":"Gao","year":"2014","journal-title":"Neoplasma"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/cr.2015.23","article-title":"miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression","volume":"25","author":"Mu","year":"2015","journal-title":"Cell Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2015.02.084","article-title":"MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib","volume":"459","author":"Zheng","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.18632\/oncotarget.3484","article-title":"Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1007\/s13277-015-3369-3","article-title":"miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma","volume":"36","author":"Long","year":"2015","journal-title":"Tumor Boil."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/mt.2015.129","article-title":"miR\u2013221\/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma","volume":"23","author":"Khella","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"78433","DOI":"10.18632\/oncotarget.12618","article-title":"MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients","volume":"7","author":"Mittmann","year":"2016","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/bjc.2017.33","article-title":"Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: A multicentre, single-arm phase I\/II clinical trial","volume":"116","author":"Pili","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"30410","DOI":"10.18632\/oncotarget.16494","article-title":"Novel potential predictive markers of sunitinib outcomes in long\u2013term responders versus primary refractory patients with metastatic clear\u2013cell renal cell carcinoma","volume":"8","author":"Puente","year":"2017","journal-title":"Oncotarget"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1159\/000484395","article-title":"Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A","volume":"43","author":"Xiao","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/1535370217701625","article-title":"MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene","volume":"242","author":"Sun","year":"2017","journal-title":"Exp. Boil. Med."},{"key":"ref_160","first-page":"2961","article-title":"Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response","volume":"38","author":"Kovacova","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21873\/cgp.20140","article-title":"MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients","volume":"16","author":"Kovacova","year":"2019","journal-title":"Cancer Genom. Proteom."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ijc.32543","article-title":"Extracellular vesicles transmitted miR\u201331\u20135p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma","volume":"146","author":"He","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"59070","DOI":"10.18632\/oncotarget.10887","article-title":"The microRNA signature of patients with sunitinib failure: Regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma","volume":"7","author":"Goto","year":"2016","journal-title":"Oncotarget"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/2159-8290.CD-11-0209","article-title":"The emergence of lncRNAs in cancer biology","volume":"1","author":"Prensner","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wang, C., Wang, L., Ding, Y., Lu, X., Zhang, G., Yang, J., Zheng, H., Wang, H., Jiang, Y., and Xu, L. (2017). LncRNA Structural Characteristics in Epigenetic Regulation. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122659"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.celrep.2016.01.073","article-title":"lncRNA-Induced Nucleosome Repositioning Reinforces Transcriptional Repression of rRNA Genes upon Hypotonic Stress","volume":"14","author":"Zhao","year":"2016","journal-title":"Cell Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.3205","article-title":"Fine-scale chromatin interaction maps reveal the cis-regulatory landscape of human lincRNA genes","volume":"12","author":"Ma","year":"2014","journal-title":"Nat. Methods"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11993","article-title":"Natural RNA circles function as efficient microRNA sponges","volume":"495","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"ref_169","first-page":"91","article-title":"The Emerging Role of Long Noncoding RNAs in Human Disease","volume":"1706","author":"Distefano","year":"2018","journal-title":"Metab. Pathw. Eng."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"730.e1","DOI":"10.1016\/j.urology.2014.05.033","article-title":"RCCRT1 Is Correlated With Prognosis and Promotes Cell Migration and Invasion in Renal Cell Carcinoma","volume":"84","author":"Song","year":"2014","journal-title":"Urology"},{"key":"ref_172","first-page":"312","article-title":"Long intergenic non-coding RNA 00152 promotes renal cell carcinoma progression by epigenetically suppressing P16 and negatively regulates miR-205","volume":"7","author":"Wang","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12943-019-1072-5","article-title":"Circ\u2013AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR\u2013296\u20133p\/E\u2013cadherin signals","volume":"18","author":"Xue","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nsmb.2942","article-title":"Discovery and annotation of long noncoding RNAs","volume":"22","author":"Mattick","year":"2015","journal-title":"Nat. Struct. Mol. Boil."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/91.2.143","article-title":"aHIF: A Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia","volume":"91","author":"Tartof","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.4161\/cc.10.18.17183","article-title":"Characterization of novel antisense HIF-1\u03b1 transcripts in human cancers","volume":"10","author":"Bertozzi","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_177","first-page":"2799","article-title":"The long non\u2013coding RNA lnc\u2013ZNF180\u20132 is a prognostic biomarker in patients with clear cell renal cell carcinoma","volume":"5","author":"Ellinger","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3892\/ol.2016.4856","article-title":"lncRNA uc009yby.1 promotes renal cell proliferation and is associated with poor survival in patients with clear cell renal cell carcinomas","volume":"12","author":"Ren","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Qin, C., Han, Z., Qian, J., Bao, M., Li, P., Ju, X., Zhang, S., Zhang, L., Li, S., and Cao, Q. (2014). Expression Pattern of Long Non-Coding RNAs in Renal Cell Carcinoma Revealed by Microarray. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099372"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13148-015-0047-7","article-title":"Identification of novel long non-coding RNAs in clear cell renal cell carcinoma","volume":"7","author":"Blondeau","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3892\/mmr.2016.4908","article-title":"Downregulation of long non-coding RNA TRIM52-AS1 functions as a tumor suppressor in renal cell carcinoma","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.3892\/mmr.2016.4894","article-title":"Identification of long-non coding RNA UCA1 as an oncogene in renal cell carcinoma","volume":"13","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1038\/oncsis.2015.48","article-title":"A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls","volume":"5","author":"Wu","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_184","first-page":"46","article-title":"Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma","volume":"22","author":"He","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"12692","DOI":"10.1038\/ncomms12692","article-title":"A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells","volume":"7","author":"Qu","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/CBM-170251","article-title":"Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma","volume":"21","author":"Bao","year":"2017","journal-title":"Cancer Biomark."},{"key":"ref_187","first-page":"1","article-title":"Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_188","first-page":"2758","article-title":"Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas","volume":"7","author":"Yao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_189","first-page":"5801","article-title":"High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_190","first-page":"3765","article-title":"Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma","volume":"8","author":"Xue","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1007\/s13277-014-2925-6","article-title":"Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma","volume":"36","author":"Zhang","year":"2014","journal-title":"Tumor Boil."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4149\/neo_2015_049","article-title":"Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma","volume":"62","author":"Wang","year":"2015","journal-title":"Neoplasma"},{"key":"ref_193","first-page":"285","article-title":"Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma","volume":"6","author":"Wu","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_194","first-page":"82","article-title":"Prognostic significance of overexpressed long non-coding RNA TUG1 in patients with clear cell renal cell carcinoma","volume":"21","author":"Wang","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.18632\/oncotarget.11011","article-title":"Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma","volume":"8","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"18657","DOI":"10.18632\/oncotarget.15703","article-title":"Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Xu, Y., Tong, Y., Zhu, J., Lei, Z., Wan, L., Zhu, X., Ye, F., and Xie, L. (2017). An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3339-9"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-017-0681-0","article-title":"Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"85353","DOI":"10.18632\/oncotarget.19743","article-title":"lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08363-6","article-title":"Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma","volume":"7","author":"Flippot","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejso.2018.01.013","article-title":"Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma","volume":"44","author":"Su","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1002\/jcb.27099","article-title":"Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR\u2013495\u20133p","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"10406","DOI":"10.1002\/jcb.27389","article-title":"LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma","volume":"119","author":"Ding","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","article-title":"Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA","volume":"29","author":"Qu","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1038\/onc.2016.356","article-title":"Long noncoding RNA\u2013SRLR elicits intrinsic sorafenib resistance via evoking IL\u20136\/STAT3 axis in renal cell carcinoma","volume":"36","author":"Xu","year":"2017","journal-title":"Oncogene"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/cdd.2017.74","article-title":"LncRNA\u2013SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)\/miRNA\u2013143\u20133p signals","volume":"24","author":"Zhai","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/15384101.2018.1475826","article-title":"Long non\u2013coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR\u201321\/SOX5 pathway","volume":"18","author":"Liu","year":"2019","journal-title":"Cell Cycle"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:57:55Z","timestamp":1760176675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":207,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082214"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082214","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]}}}